Trials / Recruiting
RecruitingNCT04347473
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
A Single Center Study to Evaluate the Effectiveness and Safety of ILUMYA in Combination With HALOG Ointment 0.1% for the Treatment of Moderate to Severe Plaque Psoriasis.
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Psoriasis Treatment Center of Central New Jersey · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.
Detailed description
25 adult subjects with moderate to severe plaque psoriasis will receive Ilumya 100mg subcutaneously at weeks 0, 4 and 16. At week 16, patients with remaining BSA ˃3% will be given HALOG ointment 0.1% to apply BID for 4 weeks. Patients who have ≤3% BSA at week 16 will remain on Ilumya monotherapy. Patients will continue to be evaluated at weeks 20 and 24.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ilumya Injectable Product | IL-23 injection |
Timeline
- Start date
- 2020-04-06
- Primary completion
- 2020-12-30
- Completion
- 2021-03-01
- First posted
- 2020-04-15
- Last updated
- 2020-04-15
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04347473. Inclusion in this directory is not an endorsement.